Sonoma Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Sonoma Biotherapeutics's estimated annual revenue is currently $28.3M per year.
- Sonoma Biotherapeutics's estimated revenue per employee is $193,750
- Sonoma Biotherapeutics's total funding is $365M.
Employee Data
- Sonoma Biotherapeutics has 146 Employees.
- Sonoma Biotherapeutics grew their employee count by -8% last year.
Sonoma Biotherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and Co-Founder | Reveal Email/Phone |
2 | CEO, President | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | EVP and Chief Medical Officer | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | SVP, Clinical Development | Reveal Email/Phone |
7 | Sr. Associate Scientist - IVP | Reveal Email/Phone |
8 | VP Clinical Operations | Reveal Email/Phone |
9 | VP, Translational Sciences | Reveal Email/Phone |
10 | VP Data Science | Reveal Email/Phone |
Sonoma Biotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Sonoma Biotherapeutics?
Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient’s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma’s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.
keywords:N/A
$365M
Total Funding
146
Number of Employees
$28.3M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sonoma Biotherapeutics News
BiotechVenture CapitalSpecial ReportsElevateBioSonoma BiotherapeuticsEQRxLarondeNeumora TherapeuticsAdagio TherapeuticsAltos LabsInsilico...
... CapitalSpecial ReportsElevateBioSonoma BiotherapeuticsEQRxLarondeNeumora TherapeuticsAdagio TherapeuticsAltos LabsInsilico Medicine.
Arrowhead and Vivo Capital are forming a new company called Visirna Therapeutics to take four of the biotech's RNAi therapies to China,...
Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing. Proceeds from the financing will be used to advance Sonoma Bio’s Treg cell therapy platform and a novel Teff cond ...
Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary regulatory T cell (Treg) therapy and effector T cell (Teff) conditioning Series B financing comprised of strong syndicate of leading life science investors Financing supports the ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $47.7M | 146 | -10% | $237M |
#2 | $32.9M | 146 | 0% | N/A |
#3 | $35.8M | 146 | 0% | $31.7M |
#4 | $23.3M | 146 | 7% | N/A |
#5 | $44.9M | 146 | 595% | $15M |